Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Subscribe To Our Newsletter & Stay Updated
